Brief Article
Copyright ©2011 Baishideng Publishing Group Co., Limited. All rights reserved.
World J Gastroenterol. Aug 14, 2011; 17(30): 3510-3517
Published online Aug 14, 2011. doi: 10.3748/wjg.v17.i30.3510
Prediction of nephrotoxicity induced by cisplatin combination chemotherapy in gastric cancer patients
Hyung Hwan Moon, Kyung Won Seo, Ki Young Yoon, Yeon Myung Shin, Kyung Hyun Choi, Sang Ho Lee
Hyung Hwan Moon, Kyung Won Seo, Ki Young Yoon, Yeon Myung Shin, Kyung Hyun Choi, Sang Ho Lee, Department of Surgery, Kosin University College of Medicine, 602-703 Busan, South Korea
Author contributions: Lee SH and Moon HH contributed mainly to this work; Lee SH designed the research; Lee SH, Choi KH, Shin YM, Yoon KY performed the research; Moon HH and Seo KW analyzed the data; Lee SH, Moon HH and Seo KW wrote the paper.
Correspondence to: Sang Ho Lee, MD, Department of Surgery, College of Medicine, Kosin University, 602-703 Busan, South Korea.
Telephone: +82-51-9906243 Fax: +82-51-2466093
Received: November 26, 2010
Revised: May 19, 2011
Accepted: May 26, 2011
Published online: August 14, 2011

AIM: To evaluate the treatment options for nephrotoxicity due to cisplatin combination chemotherapy.

METHODS: We retrospectively reviewed patients who had received cisplatin combination chemotherapy for gastric cancer between January 2002 and December 2008. We investigated patients who had shown acute renal failure (ARF), and examined their clinical characteristics, laboratory data, use of preventive measures, treatment cycles, the amount of cisplatin administered, recovery period, subsequent treatments, and renal status between the recovered and unrecovered groups.

RESULTS: Forty-one of the 552 patients had serum creatinine (SCR) levels greater than 1.5 mg/dL. We found that pre-ARF SCR, ARF SCR, and ARF glomerular filtration rates were significantly associated with renal status post-ARF between the two groups (P = 0.008, 0.026, 0.026, respectively). On the receiver operating characteristic curve of these values, a 1.75 mg/dL ARF SCR value had 87.5% sensitivity and 84.8% specificity (P = 0.011).

CONCLUSION: Cessation or reduction of chemotherapy should be considered for patients who have an elevation of SCR levels during cisplatin combination chemotherapy.

Keywords: Acute renal failure, Cisplatin, Drug toxicities, Nephrotoxicity